Abstract
Sirtuins are a family of NAD+-dependent protein deacetylases, which regulate cell survival and energy metabolism, inflammation and cancer. Recent studies have shown that sirtuin-1 (SIRT1) modulates Human Immunodeficiency Virus (HIV)-1 transcription. The HIV-1 Tat protein is a substrate for the deacetylase activity of SIRT1; SIRT1 recycles Tat to its unacetylated form, catalyzing a fundamental step to start new cycles of viral transcription. Moreover, Tat has been reported to promote T-cell hyperactivation by suppressing SIRT1 activity. In fact, Tat blocks the ability of SIRT1 to deacetylate lysine 310 in the p65 subunit of nuclear factor-κB (NF-κB) by interacting with the deacetylase domain of SIRT1. This mechanism leads therefore to the hyperactivation of NF-κB proinflammatory pathway and may likely contribute to the chronic immune activation state of HIV-infected individuals.
In the present review we first briefly describe the biological functions of sirtuins, then we delineate the interplay between SIRT1 and HIV-1 and discuss the potential role of SIRT1 as a pharmacological target of HIV-1 replication.
Keywords: Deacetylase activity, HIV-1, HDAC, resveratrol, sirtuin, SIRT1.
Current Drug Targets
Title:Sirtuin-1 and HIV-1: An Overview
Volume: 14 Issue: 6
Author(s): Marilia Rita Pinzone, Bruno Cacopardo, Fabrizio Condorelli, Michele Di Rosa and Giuseppe Nunnari
Affiliation:
Keywords: Deacetylase activity, HIV-1, HDAC, resveratrol, sirtuin, SIRT1.
Abstract: Sirtuins are a family of NAD+-dependent protein deacetylases, which regulate cell survival and energy metabolism, inflammation and cancer. Recent studies have shown that sirtuin-1 (SIRT1) modulates Human Immunodeficiency Virus (HIV)-1 transcription. The HIV-1 Tat protein is a substrate for the deacetylase activity of SIRT1; SIRT1 recycles Tat to its unacetylated form, catalyzing a fundamental step to start new cycles of viral transcription. Moreover, Tat has been reported to promote T-cell hyperactivation by suppressing SIRT1 activity. In fact, Tat blocks the ability of SIRT1 to deacetylate lysine 310 in the p65 subunit of nuclear factor-κB (NF-κB) by interacting with the deacetylase domain of SIRT1. This mechanism leads therefore to the hyperactivation of NF-κB proinflammatory pathway and may likely contribute to the chronic immune activation state of HIV-infected individuals.
In the present review we first briefly describe the biological functions of sirtuins, then we delineate the interplay between SIRT1 and HIV-1 and discuss the potential role of SIRT1 as a pharmacological target of HIV-1 replication.
Export Options
About this article
Cite this article as:
Pinzone Marilia Rita, Cacopardo Bruno, Condorelli Fabrizio, Rosa Michele Di and Nunnari Giuseppe, Sirtuin-1 and HIV-1: An Overview, Current Drug Targets 2013; 14 (6) . https://dx.doi.org/10.2174/1389450111314060005
DOI https://dx.doi.org/10.2174/1389450111314060005 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aptamer-Based Targeted Drug Delivery Systems: Current Potential and Challenges
Current Medicinal Chemistry Marine Drugs: A Hidden Wealth and a New Epoch for Cancer Management
Current Drug Metabolism Notch Signalling Pathways and Their Importance in the Treatment of Cancers
Current Drug Targets Chemotherapy-Induced Modifications to Gastrointestinal Microflora: Evidence and Implications of Change
Current Drug Metabolism Enhancing the Cytotoxic Activity of Novel Targeted Therapies – Is There a Role for a Combinatorial Approach?
Current Clinical Pharmacology Meet Our Editorial Board Member
Current Cancer Drug Targets Molecular Targets for Nutritional Preemption of Cancer
Current Cancer Drug Targets 3D-QSAR Methodologies and Molecular Modeling in Bioinformatics for the Search of Novel Anti-HIV Therapies: Rational Design of Entry Inhibitors
Current Bioinformatics Editorial (Thematic Issue: Advances in Drug Discovery for the Treatment of Cancer: Many Approaches, One Goal)
Current Topics in Medicinal Chemistry ABC Transporter Inhibitors in Reversing Multidrug Resistance to Chemotherapy
Current Drug Targets The Multiple Roles of Vitamin D in Human Health. A Mini-Review
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Olive Oil and Apoptosis of Cancer Cells
Current Nutrition & Food Science Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT
Current Pharmaceutical Design Synthesis of Isoxazole Moiety Containing Thieno[2,3-d]pyrimidine Derivatives and Preliminarily in vitro Anticancer Activity (Part II)
Anti-Cancer Agents in Medicinal Chemistry Targeting BMP9-Promoted Human Osteosarcoma Growth by Inactivation of Notch Signaling
Current Cancer Drug Targets Modulation of Angiogenesis for Cancer Prevention: Strategies Based On Antioxidants and Copper Deficiency
Current Pharmaceutical Design Recent Developments on 1,2,4-Triazole Nucleus in Anticancer Compounds: A Review
Anti-Cancer Agents in Medicinal Chemistry Engineered Peptides for Applications in Cancer-Targeted Drug Delivery and Tumor Detection
Mini-Reviews in Medicinal Chemistry Gynecomastia in Infants, Children, and Adolescents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Genetic Techniques for Pharmacogenetic Analyses
Current Pharmaceutical Design